Phase III Manufacturing Suite Now Operational — 60% Capacity Increase

Our new 30,000 sq ft Phase III GMP synthesis suite has passed FDA pre-approval inspection, expanding our commercial-scale peptide API capacity by 60%. The suite features 4 new automated SPPS reactors and a dedicated lyophilization suite capable of processing 200L batches.